Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

 

COLUMVI in combination with gemcitabine and oxaliplatin (GemOx) is indicated for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).1

 

COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.1

 

nil
Prescribing Information
Treatment pathway 2L: COLUMVI + GemOx 3L+: COLUMVI monotherapy

NICE recommends COLUMVI as monotherapy for the treatment of adult patients with R/R DLBCL, after two or more lines of systemic therapy.2

There remains an unmet need for treatments in patients who are ineligible for third line and beyond (3L+) chimeric antigen receptor T-cell therapy (CAR-T) and in patients who progress following CAR-T infusion.3,4

 

COLUMVI is the only fixed duration bispecific antibody treatment licensed for 3L+ DLBCL.*†1

 

COLUMVI engages and redirects a patient’s T-cells to help eliminate malignant B-cells.5

*3L+ DLBCL is defined as after two or more lines of systemic therapy. †Each cycle is 21 days, up to a maximum of 12 cycles (~8.5 months) or until disease progression or unacceptable toxicity.1
Expert perspectives on clinical trial data

Watch Professor Andy Davies sharing his insights on the 3 year follow up data from the NP30179 study.

 

For UK prescribing information, please click here or scan the QR code in the videos.
COLUMVI monotherapy dosing and administration guide
Click here to download a guide to the dosing, administration, and management of adverse events relating to the use of COLUMVI within its licensed indication as monotherapy for the treatment of adult patients with R/R DLBCL, after two or more lines of systemic therapy.

We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.

 

Contact our team to discuss COLUMVI
Explore more
Columvi Product
Explore where COLUMVI fits in the DLBCL treatment landscape
Content page
Watch Professor Chris Fox's overview of the STARGLO trial
Hematology Oncology Content page
Explore the Roche haematology portfolio

Abbreviations:


2L, second line; 3L+, third line and beyond; HCP, healthcare professional; NICE, National Institute for Health and Care Excellence.

 

References:

  1. COLUMVI Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. Technology appraisal guidance TA927. Published 17 October 2023.
  3. Boyle S, et al. Br J Haematol 2023;00:1–7.
  4. Kuhnl A, et al. Br J Haematol 2022;00:1–11.
  5. Dickinson M, et al. NEJM 2022:387:2220–2231.

 
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.